Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation - Wikidata - awgldk - TriplyDB

Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation

Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation

http://www.wikidata.org/entity/Q34827332

about

Nonmyeloablative allogeneic hematopoietic cell transplantation Nonmyeloablative allogeneic stem cell transplantation for non-hodgkin lymphoma Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT.Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy.Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia.Clinical significance of high-dose cytarabine added to cyclophosphamide/total-body irradiation in bone marrow or peripheral blood stem cell transplantation for myeloid malignancy.A disease risk index for patients undergoing allogeneic stem cell transplantation.Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation Haploidentical Transplantation Without In Vitro T-Cell Depletion Results in Outcomes Equivalent to Those of Contemporaneous Matched Sibling and Unrelated Donor Transplantation for Acute Leukemia The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party.Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia.Transplantation for myelodysplastic syndromes 2013.Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma.Unrelated and alternative donor allogeneic stem cell transplant in patients with relapsed or refractory Hodgkin lymphoma: a systematic review.Comparable analysis of outcomes for allogeneic peripheral blood stem cell transplantation from matched related and matched unrelated donors in acute myeloid leukemia.Impact of HLA-Mismatch in Unrelated Donor Hematopoietic Stem Cell Transplantation: A Meta-Analysis.Development and implementation of a computerized system for collection, processing, and administration of cellular therapy products.Allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning regimen for elderly patients (60 years and older) with hematologic malignancies using unrelated donors: a retrospective study from the French society for stem ce Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma.HLA-C KIR-Ligands Determine the Impact of Anti-Thymocyte Globulin (ATG) on Graft versus Host and Graft versus Leukemia Effects Following Hematopoietic Stem Cell Transplantation.Donor selection for patients undergoing allogeneic hematopoietic SCT: assessment of the priorities of Canadian hematopoietic SCT physicians Risk factors for hypogammaglobulinemia after allo-SCT Single nucleotide polymorphisms within HLA region are associated with disease relapse for patients with unrelated cord blood transplantation Matched unrelated or matched sibling donors result in comparable outcomes after non-myeloablative HSCT in patients with AML or MDS

P2860

Q26748780-ED25670A-6865-4BF8-A89D-7F5849FC6E86 Q26999011-3DE9C592-11E6-412C-8A82-FEAED95C8512 Q35583434-73F69AA6-C441-4613-9D96-BD8B61686F3C Q35800814-64E633A4-EB2F-4529-B3CE-A282AEAA4347 Q35859239-9747978C-27F7-41FA-9C16-4D12366C9EEA Q35953348-47E57630-49B2-4726-9E33-0143268FE8FB Q36025319-1CB8E8A3-1BEB-4A4B-BDFA-A8659CB1AF18 Q36141944-1EE3D3A8-A0ED-45EF-B1A3-D44543EF1A4D Q36763834-027C000C-D485-4572-A089-921D2749351D Q36822659-B90C282A-B812-4EB9-94A5-8B8DDC3DC92E Q37148409-030A7DF8-4018-4F29-A7DF-3F4FABA4A04A Q37419348-E07090EA-106C-4EE1-A047-40A88B13F89B Q37600407-47F36520-4176-4D55-A024-D0318A503EA9 Q37938531-C2400F21-A122-43BD-AB5C-62462CA38B3B Q38105131-BCA8486C-3C62-459C-8D46-DB8B716FF2D5 Q38467711-0960C846-34B1-44DE-8355-B6E6BEEFB01B Q38755378-F0AD89B2-CBCF-44BF-A042-1CEC3667133F Q42117817-F6570694-20CF-45F4-A376-68D07DA163A6 Q42397451-38770CDE-292B-42D3-A8B4-FE77871E88CF Q44943572-996A55F6-31D6-4A3E-AE2E-F875ECA9E991 Q53491938-7E7B7015-0EF4-409C-871D-785732354E48 Q58056485-EDBF7294-B30C-44E4-865B-EAD91DB1AB06 Q58470540-5BDA5974-B987-4A07-A25E-651BA75DE345 Q58803537-23716BB2-12E2-4BAB-AE42-25986A95CF45 Q58814201-88E8188E-C278-419A-AA4E-1B7F7A3BCA77

P2860

Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation

http://www.wikidata.org/entity/Q34827332

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Use of matched unrelated donor ...... etic stem cell transplantation

@ast

Use of matched unrelated donor ...... etic stem cell transplantation

@en

Use of matched unrelated donor ...... etic stem cell transplantation

@nl

type

label

Use of matched unrelated donor ...... etic stem cell transplantation

@ast

Use of matched unrelated donor ...... etic stem cell transplantation

@en

Use of matched unrelated donor ...... etic stem cell transplantation

@nl

prefLabel

Use of matched unrelated donor ...... etic stem cell transplantation

@ast

Use of matched unrelated donor ...... etic stem cell transplantation

@en

Use of matched unrelated donor ...... etic stem cell transplantation

@nl

P1433

Q34827332-B4969BBA-5A90-4630-9E08-CC6E0CB8A581

P1476

Q34827332-916CFEE8-B2B3-4205-993F-01F52173D1B2

P2093

Q34827332-12ACFF45-1B20-47C9-B424-EA6B02385269

Q34827332-24BE7C84-7447-4E9E-AE85-9EC6B488791E

Q34827332-29A71E84-0775-49ED-8FF0-720F83B68340

Q34827332-359B30E6-F404-4C2B-9942-BA5D3A4D3E33

Q34827332-3AA4A82F-AEA9-4163-9527-DE0080EB3062

Q34827332-4DFF0C8D-3F5C-41B0-8090-CFADDF991508

Q34827332-99923DE6-2B97-4F62-BC81-4ABA2E10B185

Q34827332-9C397950-7A85-4369-9C23-CDDF408193D0

Q34827332-C7EA36E1-1509-453C-BFF2-21D655F78F67

Q34827332-F09D3D3C-11EE-4AF7-8FE8-D57F1B197250

P2860

Q34827332-18B951F6-E0E7-4B53-8E48-DB2005673FAE

Q34827332-28296F43-E373-4B77-BC65-0534C70B5CAC

Q34827332-34B806AB-F458-44FE-BCEB-325371B594A9

Q34827332-3CD2CD1A-58DD-4EE7-866F-590416C9BCDF

Q34827332-41BA8BD1-5B66-4DBB-AAB4-A3C13D514856

Q34827332-918AF453-2F87-4E0D-B842-5855D2F55FF6

Q34827332-9C9EDB97-8565-4880-98B4-665A3A444197

Q34827332-A122252A-B5B6-4866-85B5-C6EF75990EEA

Q34827332-ACFC71B6-E12C-44E9-BAE8-AA8C1CBE06A4

Q34827332-AEFDD782-7ECC-4FE4-BCC2-587C9FE97112

P304

Q34827332-A3FCA2A6-D205-442A-9CBA-2D75A50C3BBA

P31

Q34827332-15BE2433-3AB8-45FE-AEF2-20719C8C3A61

P356

Q34827332-33900107-B733-4C18-8D6D-281F89D32D06

P433

Q34827332-6C4A9ECA-6E2A-4389-A18A-42C0446FDA92

P478

Q34827332-ED6E1B01-EFBA-47AC-9739-450B260A9025

P50

Q34827332-11A1F1B0-2C44-4B82-8B77-6448BF01313F

P577

Q34827332-35C04333-8084-40DE-80C3-8C304523597F

P5875

Q34827332-BCC74F13-B1D2-4DB8-B8E1-C35C8D673563

P698

Q34827332-2570596E-CBCE-4B1E-8320-6F8A71FADAE2

P932

Q34827332-FF8B3E85-9D24-4B5A-899D-D23C8D5B4861

P356

J.BBMT.2010.12.702

P1433

Biology of Blood and Marrow Transplantation

P1476

Use of matched unrelated donor ...... etic stem cell transplantation

@en

P2093

Corey Cutler

http://www.w3.org/2001/XMLSchema#string

Deborah Liney

http://www.w3.org/2001/XMLSchema#string

Edwin P Alyea

http://www.w3.org/2001/XMLSchema#string

Grace Kao

http://www.w3.org/2001/XMLSchema#string

Haesook T Kim

http://www.w3.org/2001/XMLSchema#string

John Koreth

http://www.w3.org/2001/XMLSchema#string

Joseph H Antin

http://www.w3.org/2001/XMLSchema#string

Julie Aldridge

http://www.w3.org/2001/XMLSchema#string

Philippe Armand

http://www.w3.org/2001/XMLSchema#string

Robert J Soiffer

http://www.w3.org/2001/XMLSchema#string

P2860

Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.

Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse

Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age.

Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission

Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation.

Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors.

The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.

Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantat

1994 Consensus Conference on Acute GVHD Grading

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.

P304

1196-1204

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBMT.2010.12.702

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-12-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49716252

http://www.w3.org/2001/XMLSchema#string

P698

21193054

http://www.w3.org/2001/XMLSchema#string

P932

3080446

http://www.w3.org/2001/XMLSchema#string